These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12670416)

  • 1. Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?
    Cole GM
    Neuron; 2003 Mar; 37(6):889-90. PubMed ID: 12670416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
    Kaur D; Yantiri F; Rajagopalan S; Kumar J; Mo JQ; Boonplueang R; Viswanath V; Jacobs R; Yang L; Beal MF; DiMonte D; Volitaskis I; Ellerby L; Cherny RA; Bush AI; Andersen JK
    Neuron; 2003 Mar; 37(6):899-909. PubMed ID: 12670420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Youdim MB; Stephenson G; Ben Shachar D
    Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
    Mandel S; Maor G; Youdim MB
    J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron: a new target for pharmacological intervention in neurodegenerative diseases.
    Whitnall M; Richardson DR
    Semin Pediatr Neurol; 2006 Sep; 13(3):186-97. PubMed ID: 17101458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial ferritin suppresses MPTP-induced cell damage by regulating iron metabolism and attenuating oxidative stress.
    You LH; Li Z; Duan XL; Zhao BL; Chang YZ; Shi ZH
    Brain Res; 2016 Jul; 1642():33-42. PubMed ID: 27017962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective Effect of a New 7,8-Dihydroxycoumarin-Based Fe
    Aguirre P; García-Beltrán O; Tapia V; Muñoz Y; Cassels BK; Núñez MT
    ACS Chem Neurosci; 2017 Jan; 8(1):178-185. PubMed ID: 27806193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.
    Yantiri F; Andersen JK
    IUBMB Life; 1999 Aug; 48(2):139-41. PubMed ID: 10794588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurodegenerative diseases and therapeutic strategies using iron chelators.
    Ward RJ; Dexter DT; Crichton RR
    J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease.
    Edwin Shackelford R; Manuszak RP; Heard SC; Link CJ; Wang S
    Med Hypotheses; 2005; 64(4):736-41. PubMed ID: 15694690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.
    Mochizuki H; Imai H; Endo K; Yokomizo K; Murata Y; Hattori N; Mizuno Y
    Neurosci Lett; 1994 Feb; 168(1-2):251-3. PubMed ID: 8028787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
    Weinreb O; Mandel S; Youdim MBH; Amit T
    Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect Comparison of Both Iron Chelators on Outcomes, Iron Deposit, and Iron Transporters After Intracerebral Hemorrhage in Rats.
    Wang G; Hu W; Tang Q; Wang L; Sun XG; Chen Y; Yin Y; Xue F; Sun Z
    Mol Neurobiol; 2016 Aug; 53(6):3576-3585. PubMed ID: 26099311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metals in our minds: therapeutic implications for neurodegenerative disorders.
    Doraiswamy PM; Finefrock AE
    Lancet Neurol; 2004 Jul; 3(7):431-4. PubMed ID: 15207800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron Chelation Inhibits Osteoclastic Differentiation In Vitro and in Tg2576 Mouse Model of Alzheimer's Disease.
    Guo JP; Pan JX; Xiong L; Xia WF; Cui S; Xiong WC
    PLoS One; 2015; 10(11):e0139395. PubMed ID: 26575486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of ginkgetin against neuroinjury in Parkinson's disease model induced by MPTP via chelating iron.
    Wang YQ; Wang MY; Fu XR; Peng-Yu ; Gao GF; Fan YM; Duan XL; Zhao BL; Chang YZ; Shi ZH
    Free Radic Res; 2015; 49(9):1069-80. PubMed ID: 25968939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease.
    Ayton S; Lei P; Duce JA; Wong BX; Sedjahtera A; Adlard PA; Bush AI; Finkelstein DI
    Ann Neurol; 2013 Apr; 73(4):554-9. PubMed ID: 23424051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?
    Kaur D; Andersen JK
    Aging Cell; 2002 Oct; 1(1):17-21. PubMed ID: 12882349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.